Purchase this article with an account.
V. K. Gullapalli, D. S. Chu; Efficacy and Safety of Adalimumab for Treatment of Ocular Inflammatory Diseases. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3909.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to determine the efficacy and the safety of adalimumab in the treatment of ocular inflammatory diseases.
A retrospective study of seven patients with ocular inflammation who were treated with adalimumab at our institution was done. Patients age ranged from 6 to 73 yrs (mean age: 33.3 ± 30 yrs). Patients had chronic recurrent uveitis or conjunctivitis secondary to rheumatoid arthritis (n=2), juvenile rheumatoid arthritis (n=2), Crohn’s disease and HLA-B27 (n=1), sarcoid (n=1), or ocular cicatricial pemphigoid (n=1). These patients had been previously treated with methotrexate, mycophenolate, infliximab, and/or cyclosporine; but uveitis was recurrent or persistent or patients did not tolerate the treatment. Patients received adalimumab injections at a dose of 40 mg every 1 (n=4) or 2 (n=3) week(s). Ocular inflammation and relapses as well as any side-effects were the main outcomes monitored.
Patients were followed over a period of 3 to 32 months (mean 13.9 ± 9.5 months) after initiation of adalimumab. Ocular inflammation resolved in seven out of seven patients after starting adalimumab. Six of seven patients have not had a relapse to date. One patient had a relapse when attempts were made to decrease the frequency of injections to every 5 weeks one year after starting therapy; however, inflammation subsided when frequency was increased to every 2 weeks. No side-effects were noted in any patients.
Short term results of adalimumab treatment indicate that ocular inflammation can be controlled if adequate dosage is maintained. Adalimumab appears to be well tolerated and safe.
This PDF is available to Subscribers Only